CRISPR

CRISPR2-tardbpa

ID

ZDB-CRISPR-190604-4

Name

CRISPR2-tardbpa

Previous Names

CRISPR2-tardbpl

Target

tardbpa (1)

Sequence

5' - CGCATTCGGTGTAATCATGACGG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
udm104	tardbpa

Expression

Gene expression in Wild Types + CRISPR2-tardbpa

No data available

Phenotype

Phenotype resulting from CRISPR2-tardbpa

No data available

Phenotype of all Fish created by or utilizing CRISPR2-tardbpa

Phenotype	Fish	Conditions	Figures
myotome neuromuscular junction development decreased occurrence, abnormal	tardbpa^{udm104/udm104}	standard conditions	Fig. 5 from Bose et al., 2018
fast muscle cell neuromuscular synaptic transmission process quality, ameliorated	tardbpb^fh301/+; tardbpa^{udm104/udm104}	chemical treatment by environment: Bay-K-8644	Fig. 6 from Bose et al., 2018
swimming occurrence, ameliorated	tardbpb^fh301/+; tardbpa^{udm104/udm104}	chemical treatment by environment: Bay-K-8644	Fig. 6 from Bose et al., 2018
fast muscle cell mini excitatory postsynaptic potential decreased frequency, abnormal	tardbpb^fh301/+; tardbpa^{udm104/udm104}	standard conditions	Fig. 4 , Fig. 6 from Bose et al., 2018
heart edematous, abnormal	tardbpb^fh301/+; tardbpa^{udm104/udm104}	standard conditions	Fig. 2 from Bose et al., 2018
fast muscle cell neuromuscular synaptic transmission decreased process quality, abnormal	tardbpb^fh301/+; tardbpa^{udm104/udm104}	standard conditions	Fig. 4 , Fig. 6 from Bose et al., 2018
swimming decreased occurrence, abnormal	tardbpb^fh301/+; tardbpa^{udm104/udm104}	standard conditions	Fig. 3 , Fig. 6 from Bose et al., 2018
myotome neuromuscular junction development decreased occurrence, exacerbated	tardbpb^fh301/+; tardbpa^{udm104/udm104}	standard conditions	Fig. 5 from Bose et al., 2018
fast muscle cell mini excitatory postsynaptic potential frequency, ameliorated	tardbpb^fh301/+; tardbpa^{udm104/udm104}	chemical treatment by environment: Bay-K-8644	Fig. 6 from Bose et al., 2018
whole organism decreased life span, abnormal	tardbpb^fh301/fh301; tardbpa^{udm104/udm104}	standard conditions	Fig. 2 from Bose et al., 2018
musculoskeletal movement decreased occurrence, abnormal	tardbpb^fh301/fh301; tardbpa^{udm104/udm104}	standard conditions	Fig. 3 from Bose et al., 2018
swimming decreased occurrence, exacerbated	tardbpb^fh301/fh301; tardbpa^{udm104/udm104}	standard conditions	Fig. 3 from Bose et al., 2018
fast muscle cell mini excitatory postsynaptic potential decreased frequency, exacerbated	tardbpb^fh301/fh301; tardbpa^{udm104/udm104}	standard conditions	Fig. 4 from Bose et al., 2018
heart edematous, abnormal	tardbpb^fh301/fh301; tardbpa^{udm104/udm104}	standard conditions	Fig. 2 from Bose et al., 2018
swimming normal occurrence, ameliorated	tardbpb^fh301/fh301; tardbpa^{udm104/udm104}	chemical treatment by environment: chemical substance	Fig. 3 from Bose et al., 2019
swimming decreased occurrence, abnormal	tardbpb^fh301/fh301; tardbpa^{udm104/udm104}	standard conditions	Fig. 3 from Bose et al., 2019
fast muscle cell neuromuscular synaptic transmission decreased process quality, exacerbated	tardbpb^fh301/fh301; tardbpa^{udm104/udm104}	standard conditions	Fig. 4 from Bose et al., 2018
whole organism dead, abnormal	tardbpb^fh301/fh301; tardbpa^{udm104/udm104}	standard conditions	Fig. 2 from Bose et al., 2018
myotome neuromuscular junction development decreased occurrence, exacerbated	tardbpb^fh301/fh301; tardbpa^{udm104/udm104}	standard conditions	Fig. 5 from Bose et al., 2018

Citations